Targeting the Complement Cascade: Evolving Strategies in the Management of Complement-Mediated Kidney Diseases

Program Description

Complement-mediated kidney diseases (CMKD), including atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathy (C3G), are progressive conditions stemming from dysregulated complement pathway activation. Often, patients with CMKD experience significant clinical burden, with rapid progression to end-stage kidney disease (ESKD). This severe prognosis has prompted a shift from conventional immunosuppressive strategies that do not address the underlying cause of the disease towards targeted complement inhibitors. While these complement inhibitors are effective, their use and administration introduce critical challenges for pharmacists, including concerns of infection risk management, medication access and prior authorization protocols, and smooth transitions of care. This webinar will detail the complement pathway in CMKD pathophysiology, offering a review of KDIGO guidelines, the latest clinical trial data on current and emerging treatments, and case-based scenarios to support appropriate therapy selection. Key educational pearls, including safety and risk mitigation protocols and medication access considerations, will be highlighted to support the pharmacist's role in optimizing long-term outcomes for patients with CMKD.

Target audience: Ambulatory Care Pharmacist, Health-System Pharmacist, Specialty Pharmacist

Type of activity: Application
Release date: December 23, 2025
Expiration date: December 23, 2026

Time to complete activity: 1.0 hours

Learner level: Foundational
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

1. Explain the pathophysiology and clinical presentation of complement-mediated kidney diseases (CMKD), including atypical hemolytic uremic syndrome and C3 glomerulopathy
2. Identify the mechanisms of action, efficacy, and safety profiles of current and emerging complement-targeted therapies
3. Determine the pharmacist’s role in facilitating access to therapy, managing risk of infection, and educating patients about long-term treatment considerations
4. Apply evidence-based strategies to optimize therapeutic decision-making and multidisciplinary care in CMKD management

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.10 CEU) under the ACPE universal activity number 0290-0000-25-423-H01-P. The activity is available for CE credit through December 23, 2026.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Branden D. Nemecek, PharmD, BCPS, FCCP

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA Dipti Desai, PharmD, MBA, CHCP; Macara Desai; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with commercial interests to disclose.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer

CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms